AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06095713
Drug: Pegunigalsidase-alfa
RxNorm normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT05483010
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin is commercially available.
Trial: NCT04939090
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04939090
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04766047
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of dexmedetomidine intraoperatively
Trial: NCT05520775
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide (subcutaneous)
Trial: NCT06525220
Drug: Petosemtamab
RxNorm normalized name: Petosemtamab
DrugBank: Petosemtamab (DB18948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCLA-158
Trial: NCT06525220
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized Antibody
Trial: NCT04744116
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05183126
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
Trial: NCT05183126
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time.
Trial: NCT04544189
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg (oral) once daily, in a 28-day cycle
Trial: NCT04544189
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
Trial: NCT06575699
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 133 mg liposomal bupivacaine per side for rectus sheath block
Trial: NCT06575699
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL bupivacaine 0.25% per side for rectus sheath block
Trial: NCT06575699
Drug: Bupivacaine-Hydromorphone Cassette
RxNorm normalized name: Bupivacaine-Hydromorphone Cassette
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
Trial: NCT04284839
Drug: DOAC
RxNorm normalized name: Benzamidoacetic acid
DrugBank: Robinia pseudoacacia pollen (DB10474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Trial: NCT04284839
Drug: VKA
RxNorm normalized name: METHYLPHENIDATE HCL (AVKARE) 18MG SA TAB
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Trial: NCT04950049
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: receive 2ml dexamethasone (5mg/ml)
Trial: NCT00035061
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05657132
Drug: herbal intracanal medication paste
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study the effect of costus herbal paste on enterococcus faecalis bacteria
Trial: NCT06304597
Drug: Imfinzi
RxNorm normalized name: Imfinzi
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
Trial: NCT06304597
Drug: Opdivo
RxNorm normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
Trial: NCT00000647
Drug: CD4-IgG
RxNorm normalized name: Human IGG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000647
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000647
Drug: Interferon alfa-n1
RxNorm normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04160910
Drug: 5-Hydroxytryptophan
RxNorm normalized name: 5-Hydroxytryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
Trial: NCT06534983
Drug: Autogene Cevumeran
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
Trial: NCT06534983
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
Trial: NCT06534983
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution for intravenous infusion
Trial: NCT06086522
Drug: QN-302
RxNorm normalized name: QN-302
DrugBank: QN-302 (DB18156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
Trial: NCT05106153
Drug: Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant will be administered orally as per assigned treatment sequence.
Trial: NCT05106153
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem will be administered orally as per assigned treatment sequence.
Trial: NCT06008106
Drug: tunlametinib
RxNorm normalized name: Tunlametinib
DrugBank: Tunlametinib (DB18791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg BID
Trial: NCT06008106
Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: according to investigators' suggestion
Trial: NCT05106153
Drug: Seltorexant
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seltorexant will be administered orally as per assigned treatment sequence.
Trial: NCT04524000
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.
Trial: NCT04524000
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Trial: NCT06414759
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily.
Trial: NCT06414759
Drug: Metolazone
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily.
Trial: NCT06564974
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week.
Trial: NCT05851456
Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
RxNorm normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Trial: NCT06106789
Drug: Tobramycin inhalation solution
RxNorm normalized name: Tobramycin Inhalation Solution
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital.
Trial: NCT05414201
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection
Trial: NCT05350774
Drug: IV normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV normal saline 250ml for 5 days
Trial: NCT04933149
Drug: Ketamine Infustion
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
Trial: NCT05853965
Drug: Belantamab mafodotin, Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belantamab mafodotin (IV) Venetoclax (PO)
Trial: NCT04586231
Drug: Belzutifan
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release 40 mg tablet
Trial: NCT04586231
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsule available in 4 mg and 10 mg dosages
Trial: NCT04586231
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet available in 20 mg, 40 mg and 60 mg dosages
Trial: NCT04868981
Drug: GST-HG141 tablets
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
Trial: NCT05195450
Drug: Tenofovir alafenamide fumarate
RxNorm normalized name: Tenofovir Alafenamide fumarate
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: • TAF 25 mg OD vs no treatment x 5 years and beyond
Trial: NCT05648318
Drug: Lactulose oral solution
RxNorm normalized name: lactulose Oral Solution
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
Trial: NCT05648318
Drug: PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
Trial: NCT05838560
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Trial: NCT05838560
Drug: quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Trial: NCT05470504
Drug: Pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30 mg subcutaneously every day for 4 weeks.
Trial: NCT05316155
Drug: Erdafitinib Intravesical Delivery System
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erdafitinib intravesical delivery system will be administered.
Trial: NCT06442462
Drug: SPG302
RxNorm normalized name: SPG302
DrugBank: SPG302 (DB18103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small synthetic molecule
Trial: NCT05286008
Drug: Ropivacaine at high concentration
RxNorm normalized name: AT-7519
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT05286008
Drug: Ropivacaine and dexamethasone
RxNorm normalized name: dexamethasone and antibiotics
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT05215418
Drug: VI-0521
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
Trial: NCT05215418
Drug: Phentermine
RxNorm normalized name: Phentermine
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentermine 30 mg capsule
Trial: NCT05393271
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered
Trial: NCT06312748
Drug: L-Citrulline
RxNorm normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet
Trial: NCT06312748
Drug: BH4
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10mg/kg
Trial: NCT06312748
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet
Trial: NCT06312748
Drug: Placebo for Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin-matched Placebo
Trial: NCT06178614
Drug: JNJ-87890387
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-87890387 will be administered.
Trial: NCT06637423
Drug: Sacituzumab tirumotecan
RxNorm normalized name: Sacituzumab tirumotecan
DrugBank: Sacituzumab tirumotecan (DB18777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration
Trial: NCT05312879
Drug: VX-147
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05173714
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
Trial: NCT05558098
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
Trial: NCT04968015
Drug: Cytarabine-Venetoclax Association
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation treatment with cytarabine + venetoclax
Trial: NCT04968015
Drug: Cytarabine-Idarubicin Association
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation treatment with cytarabine + idarubicin
Trial: NCT05788276
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin active tablets
Trial: NCT06470438
Drug: JNJ-88998377
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-88998377 will be administered.
Trial: NCT05201781
Drug: Cilta-cel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Trial: NCT04982445
Drug: CABENUVA
RxNorm normalized name: Cabenuva KIT
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CABENUVA will be administered IM at infusion centers/ASAs
Trial: NCT04786964
Drug: Cosibelimab
RxNorm normalized name: Cosibelimab
DrugBank: Cosibelimab (DB15770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04786964
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04786964
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04786964
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT04786964
Drug: Dexamethasone 4mg
RxNorm normalized name: DEXAMETHASONE 4MG TAB
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Trial: NCT04681677
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab
Trial: NCT05216952
Drug: Ulipristal Acetate Tablets
RxNorm normalized name: Ulipristal Acetate Tablets
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 90mg (three 30mg tablets) administered orally once
Trial: NCT05216952
Drug: Misoprostol Pill
RxNorm normalized name: misoprostol Pill
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
Trial: NCT06414681
Drug: Tagraxofusp
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
Trial: NCT06414681
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
Trial: NCT06313983
Drug: Hemay022+AI
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hemay022：orally once daily，A 21-day cycle
Trial: NCT05233722
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of 16 mg of Rapamycin tablets